Approval · Notice of Compliance 27075 · 2021
FETZIMA: Notice of Compliance 27075
Issued November 22, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27075
- Date
- November 22, 2021
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph and migrate the product monograph to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FETZIMA | Not yet assigned | — |
Medicinal ingredients
- LEVOMILNACIPRAN 20 MG per CAP
- LEVOMILNACIPRAN 40 MG per CAP
- LEVOMILNACIPRAN 80 MG per CAP
- LEVOMILNACIPRAN 120 MG per CAP